Provention Bio, Inc.
PRVB · NASDAQ
12/31/2022 | 9/30/2022 | 6/30/2022 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $1 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 1,330.3% | 1.3% | 28.6% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 95.3% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -351.6% | -3,734.7% | -3,941.7% | -4,990.3% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -307.7% | -3,728.6% | -3,959.9% | -3,787.6% |
| EPS Diluted | -0.45 | -0.34 | -0.46 | -0.35 |
| % Growth | -32.4% | 26.1% | -31.4% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |